Moderna is working on restoring investors' faith that its Covid-19 vaccine was not a one-hit-wonder. It also has to show it can get its costs under control.
READ MOREJohnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival in a Phase 3 trial, notching a key win in its rivalry against ...
READ MOREWhile FDA is implementing new accelerated approval reforms, Kaiser Permanente says the reforms do not go far enough.
READ MOREWelcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
READ MORE